Unit dose budesonide misses asthma endpoints

Map (NASDAQ:MAPP) and AstraZeneca (LSE:AZN; NYSE:AZN) said unit dose budesonide (UDB) missed the co-primary endpoints versus placebo in a Phase III trial to treat pediatric asthma. The endpoints were ...